Bio
Ben has been working as a medicinal chemist since 2011. After completing his postdoc, he joined Novartis, where he conducted discovery-phase research for oncology indications. While at Novartis, he transitioned to infectious disease drug discovery. He then joined Via Nova Therapeutics, a Novartis antiviral spinout founded by Don Ganem and Kelly Wong, when Novartis exited the infectious disease space.
創薬
Challenges and opportunities in structure-activity-relationship (SAR) studies
We chat with Ben Taft, Sr. Director of Chemistry at Via Nova Therapeutics, about SAR studies and the possible frontiers for bioactivity data.